{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:33:11Z","timestamp":1793694791219,"version":"4.5.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016016","name":"Gilead UK and Ireland Corporate Contributions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.antiviral.2026.106351","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T16:37:22Z","timestamp":1768840642000},"page":"106351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["SARS-CoV-2 resistance analyses from the Phase 3 BIRCH study of obeldesivir in high-risk nonhospitalized participants with COVID-19"],"prefix":"10.1016","volume":"247","author":[{"given":"Charlotte","family":"Hedskog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Peinovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pui Yan","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Mar\u00eda","family":"Gonz\u00e1lez Del Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7764-1741","authenticated-orcid":false,"given":"Yiannis","family":"Koullias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8473-8285","authenticated-orcid":false,"given":"Robert H.","family":"Hyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2026.106351_bib1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12967-023-03996-w","article-title":"Global landscape of SARS-CoV-2 mutations and conserved regions","volume":"21","author":"Abbasian","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.antiviral.2026.106351_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/science.adk6176","article-title":"Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus","volume":"383","author":"Cross","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2026.106351_bib3","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/s41591-025-03496-y","article-title":"Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates","volume":"31","author":"Cross","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2026.106351_bib6","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2026.106351_bib7","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/infdis\/jiad270","article-title":"Viral resistance analyses from the remdesivir phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)","volume":"228","author":"Hedskog","year":"2023","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2026.106351_bib8","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/v16040546","article-title":"No remdesivir resistance observed in the phase 3 severe and moderate COVID-19 SIMPLE trials","volume":"16","author":"Hedskog","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2026.106351_bib9","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.chembiol.2024.03.008","article-title":"SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs","volume":"31","author":"Iketani","year":"2024","journal-title":"Cell. Chem. Biol."},{"key":"10.1016\/j.antiviral.2026.106351_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239403","article-title":"Disentangling primer interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR","volume":"15","author":"Itokawa","year":"2020","journal-title":"PLoS. One."},{"key":"10.1016\/j.antiviral.2026.106351_bib11","doi-asserted-by":"crossref","first-page":"11701","DOI":"10.1021\/acs.jmedchem.3c00750","article-title":"Discovery of GS-5245 (obeldesivir), an oral prodrug of nucleoside GS-441524 that exhibits antiviral efficacy in SARS-CoV-2-infected African green monkeys","volume":"66","author":"Mackman","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2026.106351_bib28","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41586-022-05664-3","article-title":"Structural basis for substrate selection by the SARS-CoV-2 replicase","volume":"614","author":"Malone","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2026.106351_bib12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2026.106351_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105033","article-title":"Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir","volume":"188","author":"Martin","year":"2021","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2026.106351_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj4504","article-title":"The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses","volume":"16","author":"Martinez","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2026.106351_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12864-022-08358-2","article-title":"Pango lineage designation and assignment using SARS-CoV-2 spike gene nucleotide sequences","volume":"23","author":"O\u2019Toole","year":"2022","journal-title":"BMC. Genom."},{"key":"10.1016\/j.antiviral.2026.106351_bib16","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/S1473-3099(25)00238-5","article-title":"Efficacy and safety of obeldesivir in low-risk nonhospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study","volume":"25","author":"Ogbuagu","year":"2025","journal-title":"Lancet. Infect."},{"key":"10.1016\/j.antiviral.2026.106351_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00222-22","article-title":"Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants","volume":"66","author":"Pitts","year":"2022","journal-title":"Antimicrob. Agents. Chemother."},{"key":"10.1016\/j.antiviral.2026.106351_bib18","article-title":"SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants","volume":"69","author":"Rodriguez","year":"2024","journal-title":"Antimicrob. Agents. Chemother."},{"key":"10.1016\/j.antiviral.2026.106351_bib19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/v17020168","article-title":"Remdesivir and obeldesivir retain potent antiviral activity against SARS-CoV-2 Omicron variants","volume":"17","author":"Rodriguez","year":"2025","journal-title":"Viruses."},{"key":"10.1016\/j.antiviral.2026.106351_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104793","article-title":"Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites","volume":"178","author":"Shannon","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2026.106351_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2021.105153","article-title":"Longitudinal analysis of SARS-CoV-2 spike and RNA-dependent RNA polymerase protein sequences reveals the emergence and geographic distribution of diverse mutations","volume":"97","author":"Showers","year":"2022","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.antiviral.2026.106351_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo0718","article-title":"Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms","volume":"14","author":"Stevens","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2026.106351_bib23","article-title":"Efficacy and safety of obeldesivir in high-risk nonhospitalized patients with COVID-19 (BIRCH): a phase 3, randomized, double-blind, placebo-controlled study","author":"Streinu-Cercel","year":"2025","journal-title":"Clin. Infect. Dis. ciaf406"},{"key":"10.1016\/j.antiviral.2026.106351_bib5","series-title":"(remdesivir) for injection, for intravenous use [package insert]","year":"2025"},{"key":"10.1016\/j.antiviral.2026.106351_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adw0659","article-title":"The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection","volume":"11","author":"Woolsey","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.antiviral.2026.106351_bib26","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1038\/s41467-020-19055-7","article-title":"A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19","volume":"11","author":"Xie","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2026.106351_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104974","article-title":"A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2","volume":"185","author":"Zhang","year":"2021","journal-title":"Antivir. Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354226000100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354226000100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T13:15:39Z","timestamp":1774012539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354226000100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":26,"alternative-id":["S0166354226000100"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2026.106351","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2 resistance analyses from the Phase 3 BIRCH study of obeldesivir in high-risk nonhospitalized participants with COVID-19","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2026.106351","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106351"}}